Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Clover Biopharmaceuticals Ltd. ( (HK:2197) ).
Clover Biopharmaceuticals Ltd. announced the postponement of its board meeting originally scheduled for March 24, 2025, to March 31, 2025. The delay is due to the need for additional time to finalize the company’s annual results for the year ended December 31, 2024, which are crucial for evaluating the payment of a final dividend.
More about Clover Biopharmaceuticals Ltd.
Clover Biopharmaceuticals Ltd. is a company incorporated in the Cayman Islands, operating in the biopharmaceutical industry. The company focuses on developing innovative therapies and products, with a market emphasis on addressing significant medical needs.
YTD Price Performance: 34.85%
Average Trading Volume: 1,618,911
Technical Sentiment Signal: Hold
Current Market Cap: HK$421.5M
For a thorough assessment of 2197 stock, go to TipRanks’ Stock Analysis page.